Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [4] - The company is listed on both the ASX (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [4] Recent Company Highlights - Global sales increased by 172% in FY24, reaching $4.90 million, with record Travelan® sales of $4.86 million [4] - The company achieved record monthly sales of A$1.49 million in October 2024 (unaudited) [4] - Immuron is planning a Phase 2 trial for IMM-529 after receiving positive FDA pre-IND feedback [4] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting travelers' diarrhea, caused by pathogenic bacteria [5] - Travelan® is a highly purified tabletized preparation of hyperimmune bovine antibodies, effective in binding to diarrhea-causing bacteria [5] - In Australia, Travelan® is listed as a medicine for reducing the risk of travelers' diarrhea and minor gastrointestinal disorders [5] Clinical Development - IMM-124E, the active ingredient in Travelan®, is developed from the colostrum of immunized cattle and targets enterotoxigenic E. coli (ETEC) [9][10] - IMM-529 is being developed as an adjunctive therapy for recurrent Clostridioides difficile infection (CDI), targeting multiple virulence components [13][14] - Pre-clinical results for IMM-529 show promising outcomes in preventing primary disease (80% efficacy), protecting against disease recurrence (67% efficacy), and treating primary disease (78.6% efficacy) [15]
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th